Theravance has commenced Phase 2b study desined to evaluate varying doses of TD-4208 in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Theravance leveraged its multivalent approach of drug design to ...
Tags: drug, long-acting medicines, long-acting muscarinic antagonist